TD Cowen analyst Marc Frahm reiterated a Buy rating on Monte Rosa Therapeutics (NASDAQ: GLUE).The analyst commented, "GLUE announced a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE